These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 29885039)

  • 21. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Sexton J; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Nov; 76(11):1906-1910. PubMed ID: 28733473
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
    Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
    Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs.
    Paulus HE; Di Primeo D; Sharp JT; Genant HK; Weissman BN; Weisman MH; Sanda M;
    J Rheumatol; 2004 Mar; 31(3):470-81. PubMed ID: 14994390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Remission in rheumatoid arthritis patients treated with etanercept monotherapy: clinical practice and clinical trial experience.
    Cannon GW; Wang BC; Park GS; Koenig A; Collier DH; Keystone EC
    Clin Exp Rheumatol; 2013; 31(6):919-25. PubMed ID: 24237999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis.
    Gonzalez-Alvaro I; Carmona L; Balsa A; Sanmarti R; Belmonte MA; Tena X;
    J Rheumatol; 2003 Apr; 30(4):697-704. PubMed ID: 12672186
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study.
    Harrold LR; Litman HJ; Connolly SE; Kelly S; Hua W; Alemao E; Rosenblatt L; Rebello S; Kremer JM
    J Rheumatol; 2018 Jan; 45(1):32-39. PubMed ID: 29093151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients.
    Sokka T; Pincus T
    J Rheumatol; 2002 Dec; 29(12):2521-4. PubMed ID: 12465145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Number of active joints, not diagnosis, is the primary determinant of function and performance in early synovitis.
    Gerber LH; Furst G; Yarboro C; el-Gabalawy H
    Clin Exp Rheumatol; 2003; 21(5 Suppl 31):S65-70. PubMed ID: 14969053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PROMIS Fatigue short forms are reliable and valid in adults with rheumatoid arthritis.
    Bingham Iii CO; Gutierrez AK; Butanis A; Bykerk VP; Curtis JR; Leong A; Lyddiatt A; Nowell WB; Orbai AM; Bartlett SJ
    J Patient Rep Outcomes; 2019 Feb; 3(1):14. PubMed ID: 30790155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Prospective Evaluation of the Effects of Prevalent Depressive Symptoms on Disease Activity in Rheumatoid Arthritis Patients Treated With Biologic Response Modifiers.
    Rathbun AM; Harrold LR; Reed GW
    Clin Ther; 2016 Jul; 38(7):1759-1772.e3. PubMed ID: 27368116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry.
    Harrold LR; John A; Best J; Zlotnick S; Karki C; Li Y; Greenberg JD; Kremer JM
    Clin Rheumatol; 2017 Sep; 36(9):2135-2140. PubMed ID: 28718043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of socioeconomic status with treatment delays, disease activity, joint damage, and disability in rheumatoid arthritis.
    Molina E; Del Rincon I; Restrepo JF; Battafarano DF; Escalante A
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):940-6. PubMed ID: 25581770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of functional medicine on patient-reported outcomes in inflammatory arthritis: A retrospective study.
    Droz N; Hanaway P; Hyman M; Jin Y; Beidelschies M; Husni ME
    PLoS One; 2020; 15(10):e0240416. PubMed ID: 33031458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reliability and Validity of Selected PROMIS Measures in People with Rheumatoid Arthritis.
    Bartlett SJ; Orbai AM; Duncan T; DeLeon E; Ruffing V; Clegg-Smith K; Bingham CO
    PLoS One; 2015; 10(9):e0138543. PubMed ID: 26379233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors associated with the initiation of disease-modifying antirheumatic drugs in newly diagnosed rheumatoid arthritis: a retrospective claims database study.
    Bonafede MM; Fox KM; Johnson BH; Watson C; Gandra SR
    Clin Ther; 2012 Feb; 34(2):457-67. PubMed ID: 22284901
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies.
    Charles-Schoeman C; van der Heijde D; Burmester GR; Nash P; Zerbini CAF; Connell CA; Fan H; Kwok K; Bananis E; Fleischmann R
    J Rheumatol; 2018 Feb; 45(2):177-187. PubMed ID: 29142036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
    Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
    Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying Minimal and Meaningful Change in a Patient-Reported Outcomes Measurement Information System for Rheumatoid Arthritis: Use of Multiple Methods and Perspectives.
    Bartlett SJ; Gutierrez AK; Andersen KM; Bykerk VP; Curtis JR; Haque UJ; Orbai AM; Jones MR; Bingham CO
    Arthritis Care Res (Hoboken); 2022 Apr; 74(4):588-597. PubMed ID: 33166066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.